Key result
Simvastatin treatment significantly prolonged the duration of human norovirus fecal shedding (15.1 vs 8.8 days, p<0.01), whereas oral interferon-alpha reduced early viral shedding in gnotobiotic pigs.
Why the study?
Does simvastatin or interferon-alpha alter human norovirus infectivity in a gnotobiotic pig model?
Population
Young gnotobiotic piglets with A or H1 histo-blood group antigens on enterocytes, inoculated orally with a…
Design
Preclinical
Follow-up
5 days post-inoculation
Authors
Loading...
Simvastatin may increase shedding risk in norovirus patients; hypothesis-generating for interferon-alpha but human trials required before any practice change.
Does simvastatin or interferon-alpha alter human norovirus infectivity in a gnotobiotic pig model?
Absolute Event Rate: 15.1% vs 8.8%
p-value: p=<0.01
In a gnotobiotic pig model, simvastatin enhances human norovirus infectivity by inhibiting innate immunity, whereas interferon-alpha reduces infectivity, suggesting potential as an antiviral therapy.
Jung et al. (2012) studied Human Norovirus (HuNoV) infection (n=41). Simvastatin vs. Untreated (HuNoV alone) was evaluated on Duration of HuNoV fecal shedding (p=<0.01). Simvastatin treatment significantly prolonged the duration of human norovirus fecal shedding (15.1 vs 8.8 days, p<0.01), whereas oral interferon-alpha reduced early viral shedding in gnotobiotic pigs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: